Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study

Archive ouverte

Kerber, R. | Lorenz, E. | Duraffour, S. | Sissoko, Daouda | Rudolf, M. | Jaeger, A. | Cisse, S. D. | Camara, A. M. | Miranda, O. | Castro, C. M. | Akoi Bore, J. | Raymond Koundouno, F. | Repits, J. | Afrough, B. | Becker-Ziaja, B. | Hinzmann, J. | Mertens, M. | Vitoriano, I. | Hugh Logue, C. | Bottcher, J. P. | Pallasch, E. | Sachse, A. | Bah, A. | Cabeza-Cabrerizo, M. | Nitzsche, K. | Kuisma, E. | Michel, J. | Holm, T. | Zekeng, E. G. | Cowley, L. A. | Garcia-Dorival, I. | Hetzelt, N. | Baum, J. H. J. | Portmann, J. | Carter, L. | Yenamaberhan, R. L. | Camino, A. | Enkirch, T. | Singethan, K. | Meisel, S. | Mazzarelli, A. | Kosgei, A. | Kafetzopoulou, L. | Rickett, N. Y. | Patrono, L. V. | Ghebreghiorghis, L. | Arnold, U. | Colin, Geraldine | Juchet, Sylvain | Levy-Marchal, Claire | Kolie, J. S. | Beavogui, A. H. | Wurr, S. | Bockholt, S. | Krumkamp, R. | May, J. | Stoecker, K. | Fleischmann, E. | Ippolito, G. | Carroll, M. W. | Koivogui, L. | Magassouba, N. | Keita, S. | Gurry, C. | Drury, P. | Diallo, B. | Formenty, P. | Wolfel, R. | Caro, A. D. | Gabriel, M. | Anglaret, Xavier | Malvy, Denis | Gunther, S.

Edité par CCSD ; Oxford University Press -

International audience. BACKGROUND: In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. Cycle threshold (Ct) in the Ebola virus RT-PCR and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to EVD patients on compassionate use basis. METHODS: To reduce biases in the raw field data, we carefully selected 163 of the 286 EVD patients for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry, favipiravir treatment, and outcome. RESULTS: The case fatality rate in favipiravir-treated patients was lower than in untreated patients (31/73 [42.5%] vs. 52/90 [57.8%], p = 0.053 in univariate analysis). In the multivariate regression analysis, higher Ct value and younger age were associated with survival (p <0.001), while favipiravir treatment showed no statistically significant effect (p = 0.11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (p = 0.015). The study also showed characteristic changes in blood chemistry in fatal cases vs. survivors. CONCLUSIONS: Consistent with the JIKI trial, this retrospective study reveals a trend toward improved survival in favipiravir-treated patients; however, the effect was not statistically significant except for survival time.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion